All
Caspofungin adds to aspergillosis armamentarium
August 1st 2002New Orleans - The novel antifungal agent caspofungin (Cancidas) is a helpful addition to the armamentarium of medications that are currently used to treat aspergillosis, according to Tamara Koss, M.D. It may be a particularly appropriate modality in immunocompromised patients who have not responded to conventional antimycotics, she said.
Oral antihistamines not a cure for all cutaneous itching
August 1st 2002New Orleans - As antipruritic drugs, newer second-generation oral antihistamines, including loratadine (Claritin), cetirizine (Zyrtec), fexofenadine (Allegra), and desloratadine (Clarinex), offer several advantages compared with their predecessors. However, clinicians should be aware that these newer compounds are neither all alike nor routinely effective for controlling all types of cutaneous itch, Michael D. Tharp, M.D., said at the annual meeting of the American Academy of Dermatology.
AMA one step closer to funding physicians' union
August 1st 2002Washington - The executive committee of the Board of Directors of the American Medical Association approved the operating budget for Physicians for Responsible Negotiation, the physician's union launched by the AMA in 1999. The final vote from the full board was expected to take place in late July, and advocates were optimistic about the recommendation from the executive committee.
Outlook good for Medicare patients, fee cuts
August 1st 2002Despite continued concerns over terrorism and shenanigans by corporate executives that have sent the stock markets tumbling, there is some good news for dermatologists from Washington this summer. By the end of this session of Congress, there is a good chance that last year's Medicare fee cuts will be fixed and that Medicare patients will be given some form of prescription drug coverage.
Patient glut keeps derms neighborly
August 1st 2002There is no denying the atmosphere of providing medical care in this country has changed. Increased government regulations, large managed care companies and their restrictions, turf battles, and hospital chains have reduced physician control of medical care and increased competition for patients.
Can we stem the antibiotic tide?
August 1st 2002Two recent experiences have prompted me to tilt at still another windmill - that of overuse of systemic antibiotics. The first occurred two weeks ago when my neighbor and friend asked me to evaluate him for a three-day history of a persistent headache. (Why is a dermatologist doing this?) A clinical examination revealed right supraorbital tenderness and a normal neurologic condition, including full function of the right eye muscles and pupils. A clinical diagnosis of right frontal sinusitis was made and he was started on azithromycin.
Medical press releases may exaggerate results
July 29th 2002Hanover, N.H. - Some medical press releases use formats that exaggeratethe perceived importance of findings and do not routinely highlight studylimitations, according to a study published in a recent issue Journal ofthe American Medical Assn.
Cancer vaccine gets orphan drug status
July 26th 2002Antigenics Inc. reports the U.S. Food and Drug Administration grantedthe company's personalized cancer vaccine (Oncophage) orphan drug statusfor the treatment of metastatic melanoma. This offers the company potentialmarket exclusivity for seven years from FDA marketing approval.
Beauty products can cause birth defects
July 25th 2002Washington­ - A recent study revealed that many over-the-counterbeauty products can cause birth defects. In fact, 72 percent of 72 productstested by three environmental and advocacy groups were found to containdangerous chemicals called phthalates.
Searching for scientific support in AD research
July 1st 2002New Orleans - Atopic dermatitis is a frustrating condition to treat,and many frequently employed interventions lack scientific support. Thiswas the rationale behind a systematic review of all randomized, controlledtrials of AD conducted by the United Kingdom Department of Health and presentedat the American Academy of Dermatology annual meeting by Hywel Williams,Ph.D.
Cromolyn shows potential for topical itch relief
July 1st 2002Pilot study shows nine patients with pruritus respond well to topicalmast cell stabilizerNew Orleans - Results of a pilot study suggest the mast cell stabilizercromolyn may be an innovative new topical therapy for itch, Larry E. Millikan,M.D., said.
Skincare outlined in terms of health, defense
July 1st 2002As Congress tries desperately to balance the need to increase spendingfor homeland defense, lawmakers must still deal with the pressing needsof ongoing, but crucial, programs, such as research into the causes of cancerand other dreaded diseases.
Head lice: Growing problem has few good Tx options
July 1st 2002Resistance to OTC treatments has doctors seeking reliable treatments,patients creating own Miami Beach, Fla. - The epidemic of resistant head lice in theUnited States is real and only one or two of the handful of products availableto treat head lice and nits reliably rid patients of the pests, Ronald C.Hansen, M.D., said here at the annual Masters of Pediatrics meeting.
Pulsed dye laser eradicates BCC
July 1st 2002Atlanta - Preliminary research results from a pilot study showbasal cell carcinoma may be eradicated by pulsed dye laser. The study wasdiscussed by Karl R. Beutner, M.D., Ph.D., here at the annual meeting ofthe American Society of Laser Medicine and Surgery.